InvestorQ : What explains such a sharp growth in the profits of Aurobindo Pharma?
Dilmini Mercia made post

What explains such a sharp growth in the profits of Aurobindo Pharma?

Answer
image
Dawn Cherian answered.
2 months ago
Follow

Aurobindo Pharma reported a 4-fold growth in net profits to Rs.2,946 crore in the Dec-20 quarter, largely on the back of exceptional gains. The one-time gain of Rs.2,814 crore came from the disposal of Natrol LLC which is a fully owned step-down subsidiary of Aurobindo in the US.

The top line growth of 8% in the Dec-20 quarter was dominated by 6.8% growth in the US formulations business. The European formulations grew by 13.2% while revenues from the active pharma ingredients or APIs were lower by 13%. PAT margins expanded from 11.97% to 46.29%, but the gratify story was R&D expenses touching 6.1% of total sales in Q3.

0 Views